Press Releases

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

Posted on January 4, 2024

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

Posted on January 3, 2024

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program

Posted on October 10, 2023

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Posted on September 7, 2023

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Posted on August 29, 2023

INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update

Posted on August 9, 2023

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

Posted on July 26, 2023

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Posted on June 23, 2023

INOVIO to Present at the 2023 Jefferies Healthcare Conference

Posted on May 25, 2023

INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Posted on May 23, 2023

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.